- [Interview] "Recently secured KRW 5.7 billion CDMO contract for customized AAV gene therapy development and production"
- "Partnering with Korea Research Institute of Bioscience and Biotechnology (KRIBB) to deliver global-level results through technological excellence"
- "Also signed CDMO agreement with CELLinCELLS for organoid therapy clinical drug production"
[by Lee, Young Sung] “Until recently, all domestic Adeno-Associated Virus (AAV) development has depended entirely on overseas contract development and manufacturing organizations (CDMOs).”
“The signing of the first GMP-level consignment production contract for AAV by 무료 바카라 게임 holds significance that extends beyond the mere acquisition of a manufacturing agreement.”
무료 바카라 게임 has demonstrated its position as the leading CDMO in the field of cell gene therapy (CGT) by securing two contracts for the production of human administration-grade AAV CDMO vectors in Korea. Beyond its CDMO operations, the company is actively engaged in proprietary novel drug research and development (R&D), establishing a robust and diversified revenue model through the integration of multiple business streams.
The recent contract secured by 무료 바카라 게임 involves the production of an AAV vector developed by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and entrusted to 무료 바카라 게임 for CDMO services. AAV serves as a critical vector for gene delivery in the treatment of genetic disorders. Despite its importance, challenges in production and quality control (QC) have hindered domestic capabilities, resulting in a reliance on overseas manufacturers. Regarding this agreement, 무료 바카라 게임 CEO Chang Jong-wook highlighted that it represents “a collaborative effort between the public and private sectors to advance AAV production in Korea.”
The contract is valued at around KRW 5.7 billion (approximately USD 4.1 million), representing nearly 80% of 무료 바카라 게임’s total annual revenue of KRW 7.2 billion in the previous year, making it the company’s largest single contract to date. When including VAT, the total contract amount reaches approximately KRW 6.2 billion.
In an interview with <THE BIO on July 9, held near the company’s headquarters in Munjeong-dong, Songpa District, Seoul, Chang explained, “At present, most AAV-based treatments approved in the United States are imported products, with prescription costs exceeding several hundreds of millions of won. However, the domestic CGT industry has remained virtually undeveloped in the field of AAV.”
“Importantly, this revenue does not stem from research funding obtained through participation in a national project but rather constitutes direct sales generated through the development and production contract independently secured with KRIBB,” Chang further emphasized. “This is the first stepping stone for public-private collaboration aimed at establishing domestic production of commercial-grade AAV and enabling the development of homegrown treatments.” Accordingly, the initiative is expected to reduce the nation’s reliance on overseas AAV suppliers and alleviate the financial burden of insurance costs associated with the use of imported AAV-based treatments. Under this project, 무료 바카라 게임 will oversee the entire process, from process development to GMP grade clinical sample production.
“While many companies have recently entered the CDMO business (latecomers), most competitors have repurposed existing facilities originally intended for their own pipeline production into CDMOs, which poses limitations in adapting to new products,” Chang noted. “In contrast, 무료 바카라 게임’s infrastructure, including its facilities, technologies, and personnel, was purpose-built exclusively for CDMO operations, enabling the company to flexibly accommodate a diverse range of products, including cells, viral vectors, stem cells, and exosomes.”
무료 바카라 게임 is also conducting contract development and production in the emerging field of ‘organoids,’ which is gaining increasing attention in the global market.
“무료 바카라 게임 is also engaged in GMP production for organoid-based treatments,” Chang stated. “We are manufacturing clinical samples at 무료 바카라 게임, which are currently being used in ongoing clinical trials.” He further noted that, in June, 무료 바카라 게임 signed a CDMO agreement with CELLinCELLS, a developer specializing in organoid therapeutics, for the production of clinical trial materials.
무료 바카라 게임 is the only company in Korea capable of simultaneously producing cells and viral vectors in a globally certified GMP facility. By offering a differentiated manufacturing and quality management system alongside integrates one-stop services, the company delivers optimal CDMO solutions to its clients.
In particular, 무료 바카라 게임 is the first company in Korea to establish a business model that covers both CDMO services and novel drug development. “Companies that concentrate solely on new drug development face higher levels of risk. Therefore, 무료 바카라 게임 is pursuing a dual-track strategy that integrated both ‘CDMO’ operations and proprietary ‘new drug development,’” Chang emphasized.
Chang is currently a professor of convergence medicine at Samsung Medical Center and Sungkyunkwan University. He explained that his commitment to CGT business was shaped by his experience in the hospital setting.
“Witnessing firsthand the remarkable recovery of patients with genetic disorders treated with CGT at the hospital left no doubt in my mind about the potential of the CGT field,” Chang said. “I am confident that the future of the pharmaceutical industry lies in the CGT sector, and 무료 바카라 게임 is poised to grow into a global enterprise as a leading company in Korea,” he added.